Table 6.
OS according to baseline serum levels and CEA, CYFRA and NSE reduction ≥ 20%
| Mean OS (95% CI)a (months) | p-value | |
|---|---|---|
| Baseline CEA | ||
| < 5 | 12.2 (8.1–16.0) | 0.035 |
| ≥ 5 | 5.6 (2.9–8.2) | |
| Baseline CYFRA21-1 | ||
| < 3.3 | 13.2 (11.0–14.3) | 0.005 |
| ≥ 3.3 | 5.6 (3.4–7.7) | |
| Baseline NSE | ||
| < 13.4 | 10.0 (6.2–13.7) | 0.028 |
| ≥ 13.4 | 2.2 (0.2–5.0) | |
| CEA reduction ≥ 20% a | ||
| No | 9.9 (8.5–11.3) | 0.026 |
| Yes | 15.0 (12.7–17.3) | |
| CYFRA21-1 reduction ≥ 20% a | ||
| No | 10.0 (8.4–11.6) | 0.019 |
| Yes | 14.6 (12.4–16.8) | |
| NSE reduction ≥ 20% a | ||
| No | 11.6 (9.9–13.4) | 0.950 |
| Yes | 12.4 (9.8–15.0) | |
aMedian survival not reached